{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-25-000084","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.728105+00:00","generated_at":"2026-05-16T19:54:57.736248+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AEON Biopharma reports positive ABP-450 biosimilarity data, secures $6M PIPE and debt reduction","bullets":["ABP-450 shows 100% amino-acid sequence identity to BOTOX (93-99% coverage across five proteins) and highly similar functional characteristics.","FDA Type 2a meeting scheduled for November 19, 2025 to review analytical package ahead of biosimilar pathway.","$6M PIPE and Daewoong note exchange expected to reduce outstanding debt by over 90% and extend cash runway into Q2 2026.","Cash and equivalents $5.9M as of Sep 30, 2025; combined financing expected to fund operations through Q2 2026.","ABP-450 has global approval in 69 countries, supporting fully scaled manufacturing platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-25-000084","json":"https://secwatch.observer/filing/0001837607-25-000084.json","markdown":"https://secwatch.observer/filing/0001837607-25-000084.md","text":"https://secwatch.observer/filing/0001837607-25-000084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/0001837607-25-000084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:54:57.736248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}